Investments
Commented by Stefan Feulner on October 26th, 2022 | 10:15 CEST
BioNTech, Defence Therapeutics, MorphoSys - The rebound is on the way
The biotech sector is a growth market and, therefore, extremely capital-intensive. Due to the stricter monetary policy of the central banks, investors have given the promising sector the cold shoulder in recent months. Sector indices lost around 30% of their value, while the prices of individual stocks with a full development pipeline halved. The fact that several promising long-term companies are already trading below their cash levels shows that the panic is exaggerated. There are signs of a bottoming out, which could herald the next upward wave.
Read
Commented by Stefan Feulner on October 25th, 2022 | 11:26 CEST
Varta, Barsele Minerals, Nel ASA - Hard-hitting announcements from analysts
The suspense is rising - the third quarter number season is open. It will be interesting to see how companies from various sectors have performed in the months from July to September despite imponderables such as rising raw material and energy costs and the global economic downturn. Due to the partly horrendous share price losses in recent months, interesting buying opportunities could arise at a cheaper level, which should promise high price gains in the long term.
Read
Commented by André Will-Laudien on October 24th, 2022 | 12:17 CEST
US equities reporting season: Netflix, Snap, Meta Platforms, Aspermont - Will it continue explosively?
In October, the reporting season for the 3rd quarter started in the USA. This is a highly exciting time, as moves of up to 25% or more are not uncommon when a NASDAQ stock grossly deviates from its guidance. After years of bliss in the tech sector, a new parameter has also crept into the valuation of growth stocks: Interest rates. Discounted future cash flows represent the value of a stock today. If these are adjusted downward and valued at a higher discount due to increased interest rates, this can trigger significant price corrections in an emergency. Of course, this scenario also applies to upside surprises - a reason for further research.
Read
Commented by Juliane Zielonka on October 20th, 2022 | 11:41 CEST
TubeSolar, BASF, Nordex - Mastering the energy turnaround with these shares
Innovative photovoltaic companies like TubeSolar are defying the crisis. Their patented solar tube systems enable a double use of open spaces. The application thus brings farmers double profit: both through farming and additionally through the generation of solar power. The latest coup of the Landwind Group, together with Nordex AG, also proves how valuable energy generation is in this European crisis. A total of 12 wind turbines will generate 81.6 MW of electricity in the future. Companies like BASF AG are feeling the exploding electricity prices. Therefore, the red pencil is applied to save EUR 500 million per year outside of production. Will the Ludwigshafen am Rhein site remain?
Read
Commented by Nico Popp on October 13th, 2022 | 11:27 CEST
Your crash, our chance: Vonovia, Aspermont, Deutsche Bank
UBS warns that real estate prices in Frankfurt am Main and Munich are too high. Industry insiders also see hard traces of braking on the real estate market elsewhere. For a long time, real estate was considered a safe investment class for the wealthy. The trend was upward for many years. Nowhere else was it so easy to park capital and generate income. But now everything is changing. Shares, like those of the real estate company Vonovia, have already come back. We shed light on the sector and show alternatives.
Read
Commented by Stefan Feulner on October 10th, 2022 | 10:43 CEST
BioNTech, Fonterelli GmbH & Co KGaA, Fonterelli SPAC 2 AG, MorphoSys - Bullish forecasts
The capital-intensive biotech and pharma sector has been stuck in a correction since the central banks changed their strategy at the beginning of the stock market year. In particular, vaccine manufacturers, which have exploded since the outbreak of COVID-19, have lost disproportionately in value since their highs in August of last year. However, the pandemic is likely to be with us for the next few years, albeit in a weakened form. The development of new drugs benefits companies that could now face a similar path as the vaccine producers.
Read
Commented by Armin Schulz on October 6th, 2022 | 10:42 CEST
ProSiebenSat.1 Media, Aspermont, Alibaba - Growth stocks with significant rebound potential
On Friday, September 30, a key support level in the S&P 500 seemed to have fallen, but it was a false breakout, as could be seen the following Monday. A popular move by big players in the market who want to fish stops and then buy in cheaply. After the panic, the FOMO (fear-of-missing-out) phenomenon occurs. Investors who are stopped out realize their mistake and try to get back into the market as quickly as possible so as not to miss the rise. To do this, investors who have shorted the market close their positions, providing additional upside. Now it is a matter of finding the stocks that have been punished too much. We take a look at three growth stocks today.
Read
Commented by Stefan Feulner on October 4th, 2022 | 11:59 CEST
RWE, Pathfinder Ventures, United Internet - Panic as an opportunity
Last week, the crash prophets crawled out of their caves and outdid themselves with forecasts reaching the Corona lows at around 8,000 points in the leading German DAX index. Without a doubt, the general conditions for a sustained stock rally are moderate with the escalation of the Ukraine situation and concerns about further interest rate hikes. Nevertheless, there are attractive entry opportunities at the current level, which could pay off in cash in the long term.
Read
Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST
Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life
About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...
Read
Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST
Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check
The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.
Read